Business of Supply  Madam Chair, I would love to continue that conversation with the minister. As the minister knows, Canada also has one of the highest rates of MS in the world, with more than 90,000 Canadians living with this disease. Of course, while the cause is still unknown, emerging research has highlighted the potential for significant advancements in the prevention of MS.

Business of Supply  Madam Chair, I appreciate the minister for meeting with representatives from MS Canada. It is best that he hear from them directly rather than from me, but it also good to know that there are parliamentarians on all sides who are keen to see the investment made potentially, for example, in the next fall economic statement.

Business of Supply  Madam Chair, can the minister share more about what can be done in working with provinces and territories to address this seeming gap? The issue, it seems, is that Noor cannot access the drug because it is approved by Health Canada but not listed by the Canadian drug agency as recommended for public coverage.

Business of Supply  Madam Chair, absolutely, I would be happy to do that. I appreciate the specificity. I would next like to ask about Dylan and Kim. They are two of many parents in my community who have shared with me what it is like to raise a child living with CF. In their case, it is their son Jackson.

Business of Supply  Madam Chair, as the minister likely knows, because the word “pharmacare” is restricted to contraceptives and diabetes, I hesitate to use it at this point. I know that is the minister's vision for where he wants it to go. However, I am thinking about parents, such as Dylan and Kim, who want to understand more about when this could be expanded to them.

Business of Supply  Madam Chair, would the minister or a member of his team be open to accept a meeting with ACCKWA to hear directly from it about how important the support is for these test kits?

Business of Supply  Madam Chair, I need to move to the next question. My next question is on a concerning limitation in Bill C-64 brought to me by a senior in my community. The bill, of course, is designed to provide coverage for specific prescription drugs and products intended for contraception and the treatment of diabetes.

Business of Supply  Madam Chair, I am encouraged to hear that on both fronts. I appreciate that. I would like to tell the minister about another constituent of mine, Noor Ayesha. Noor is battling an incurable rare cancer. For it, she requires an oral drug. The name is Pemazyre. It has been approved by Health Canada but is not recommended by the Canadian drug agency for public coverage.

Business of Supply  Madam Chair, as I begin this evening, I want to recognize that both ministers have been, for over three hours now, providing answers of substance to all parliamentarians, and I appreciate them for that. I would like to start by following up on a letter I sent to the Minister of Health.

Petitions  Mr. Speaker, it is an honour to rise to present a petition on behalf of folks who are concerned with the number of deaths across the country as a result of poisoned drugs, a crisis that is hitting my community particularly hard. Petitioners note that they call on the Government of Canada to, first of all, declare a public health emergency with respect to overdose deaths.

Fall Economic Statement Implementation Act, 2023  Madam Speaker, first of all, we agree with the Bloc Québécois on the fact that the government needs to eliminate all oil subsidies, including those pertaining to carbon capture and storage. As a Green Party government, we would be much more ambitious. We would move more quickly and take this issue more seriously.

Fall Economic Statement Implementation Act, 2023  Madam Speaker, I can start by saying that I appreciate the member for Edmonton West's bringing up something we agree on, which is how poorly rolled out the net zero accelerator fund is. I raised that at committee. What is a qualitative GHG reduction? It does not make any sense at all.

Fall Economic Statement Implementation Act, 2023  Madam Speaker, as the parliamentary secretary knows, the amendment in front of us is, of course, not a substantive amendment. It is one of the tactics that is available to parties in this place, in this case, to delay legislation. I would also point out that it is the governing side that has the legislative power and calendar to set the agenda of the House.

Fall Economic Statement Implementation Act, 2023  Madam Speaker, I will be sharing my time. I am glad to have the chance to rise to share more about why Greens cannot support this amendment, but we will continue to support Bill C-59, the fall economic statement, despite its imperfections. Let us be clear: The amendment is essentially saying not to move forward with Bill C-59 at all in its entirety and, instead, to just repeal the carbon tax under the guise that this would help people across the country deal with issues with respect to the unaffordability of day-to-day life.

Privilege  Mr. Speaker, I have just one question for my friend opposite concerning a clarification. He said at the end of his speech that the Speaker does not have the confidence of the House. I understand that the Speaker does not have the confidence of the Conservative Party. Is that what he meant?